迈普医学（301033）披露拟收购易介医疗100%股权并募集配套资金，12月26日股价上涨0.01%

Core Viewpoint - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is planning to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. for a total price of 334.85 million yuan, which includes both share issuance and cash payment [1][2]. Group 1: Transaction Details - The transaction price is set at 33,484.94 million yuan, with 30,105.88 million yuan paid in shares and 3,379.06 million yuan in cash [1]. - The company will issue 7,271,946 shares, representing 9.84% of the total share capital post-issuance (excluding supporting financing) [1]. Group 2: Funding and Purpose - The company plans to raise an additional 13,357.64 million yuan from its controlling shareholder Yuan Yuyu to supplement working capital, fund R&D projects, and cover cash payments [2]. - This restructuring aims to expand the company's presence in the neuro-interventional medical device sector, enhancing technological synergy and channel integration [2]. Group 3: Regulatory Aspects - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring or a restructuring listing [2]. - The transaction is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, indicating potential uncertainties in implementation [2].